Doctors for the first time can determine which medication is more likely to help a patient overcome depression, according to research that pushes the medical field beyond what has essentially been a guessing game of prescribing antidepressants.
A blood test that measures a certain type of protein level provides an immediate tool for physicians who until now have relied heavily on patient questionnaires to choose a treatment, said Dr. Madhukar Trivedi, who led the research at UT Southwestern Medical Center’s Center for Depression Research and Clinical Care.
“Currently, our selection of depression medications is not any more superior than flipping a coin, and yet that is what we do. Now we have a biological explanation to guide treatment of depression,” said Dr. Trivedi, Director of the depression center, a cornerstone of UT Southwestern’s Peter O’Donnell Jr. Brain Institute.
The study demonstrated that measuring a patient’s C-reactive protein (CRP) levels through a simple finger-prick blood test can help doctors prescribe a medication that is more likely to work. Utilizing this test in clinical visits could lead to a significant boost in the success rate of depressed patients who commonly struggle to find effective treatments.
A major national study Dr. Trivedi led more than a decade ago (STAR*D) gives insight into the prevalence of the problem: Up to a third of depressed patients don’t improve during their first medication, and about 40 percent of people who start taking antidepressants stop taking them within three months.
“This outcome happens because they give up,” said Dr. Trivedi, whose previous national study established widely accepted treatment guidelines for depressed patients. “Giving up hope is really a central symptom of the disease. However, if treatment selection is tied to a blood test and improves outcomes, patients are more likely to continue the treatment and achieve the benefit.”
The new research published in Psychoneuroendocrinology measured remission rates of more than 100 depressed patients prescribed either escitalopram alone or escitalopram plus bupropion. Researchers found a strong correlation between CRP levels and which drug regimen improved their symptoms:
- For patients whose CRP levels were less than 1 milligram per liter, escitalopram alone was more effective: 57 percent remission rate compared to less than 30 percent on the other drug.
- For patients with higher CRP levels, escitalopram plus bupropion was more likely to work: 51 percent remission rate compared to 33 percent on escitalopram alone.
Dr. Trivedi noted that these results could readily apply to other commonly used antidepressants.
“These findings provide evidence that a biological test can immediately be used in clinical practice,” he said.
Dr. Trivedi identified CRP as a potential marker for depression treatments because it has been an effective measure of inflammation for other disorders such as cardiovascular disease and diabetes.
While previous research to establish CRP as an antidepressant marker used levels three to five times higher than the latest study, “my theory was that you don’t need that high of an inflammation to experience the sickness of depression,” Dr. Trivedi said. “Even a little inflammation may be sufficient for the patients to experience some of these symptoms of depression.”
The next step is to conduct larger studies to verify CRP’s role with other antidepressants and find alternative markers where CRP does not prove effective. Dr. Trivedi said these studies could lead to additional useful biological tests that can be used in practice.
“Both patients and primary-care providers are very desperately looking for markers that would indicate there is some biology involved in this disease. Otherwise, we are talking about deciding treatments from question-and-answer from the patients, and that is not sufficient,” said Dr. Trivedi, a Professor of Psychiatry who holds the Betty Jo Hay Distinguished Chair in Mental Health and is the inaugural holder of the Julie K. Hersh Chair for Depression Research and Clinical Care.
The data reviewed for the study came from the CO-MED trial, which was funded by the National Institute of Mental Health. The work was also supported through UT Southwestern’s Center for Depression Research and Clinical Care and The Hersh Foundation.
Other UT Southwestern researchers include Dr. Manish Jha, Dr. Abu Taher Minhajuddin, Dr. Bharathi Gadad, Dr. Tracy Greer, Bruce Grannemann, Dr. Abigail Soyombo and Taryn Mayes. Dr. A. John Rush, Professor Emeritus, Duke-National University of Singapore also collaborated on the publication.
“With advances in technology and our understanding of the biology of depression, our ongoing work with additional biomarkers is likely to yield tests for other subtypes of depression,” said Dr. Jha, Assistant Professor of Psychiatry.
Learn more: Blood test unlocks new frontier in treating depression
[osd_subscribe categories=’depression’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “DEPRESSION”‘]
The Latest on: Depression
[google_news title=”” keyword=”depression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Depression
- New guidelines for depression care emphasize patient-centered approach in Canadaon May 8, 2024 at 1:33 pm
Psychiatrists and mental health professionals have a new standard for managing major depression, thanks to refreshed clinical guidelines published today by the Canadian Network for Mood and Anxiety ...
- Black Women Over 50: Menopause Could Be Causing Your Depressionon May 8, 2024 at 1:00 pm
Studies find that women transitioning through menopause are at a higher risk of developing depressive symptoms. One study in the Journal of Clinical Endocrinology & Metabolism revealed that Black ...
- Ketamine Noninferior to ECT for Outpatients With Major Depressionon May 8, 2024 at 12:44 pm
NEW YORK CITY -- Treatment with ketamine was noninferior to electroconvulsive therapy (ECT) for major depressive disorder, two meta-analyses showed, though it was inferior for patients hospitalized ...
- Alanis Morissette says she felt like she was 'slowly dying' amid postpartum depression: 'It's like your whole self disappears'on May 8, 2024 at 12:34 pm
The Canadian singer talked about her experience as a mother-of-three on the "Mom and Mind" podcast's latest episode.
- Psychedelic Toad Venom Shows Promise for New Depression Treatmenton May 8, 2024 at 12:00 pm
Scientists have mapped the structure of a psychedelic drug derived from the Colorado River toad, which seems to have antidepressant effects.
- Serotonergic neuron findings suggest possible treatment for depression-related infertilityon May 8, 2024 at 11:12 am
They identified signaling from serotonergic neurons as important for maintaining reproductive function by sensing glucose availability and subsequently enhancing the release of the reproductive ...
- New device that emits magnetic field may offer hope for treating depressionon May 8, 2024 at 9:38 am
A head-mounted device that generates an ultra-low frequency ultra-low magnetic field has been found to improve the symptoms of four male patients diagnosed with major depressive disorder. Future ...
- Psychedelic Toad Venom Could Be Used To Treat Depression Based On New Evidenceon May 8, 2024 at 9:36 am
Modern science has dreamed up a wide variety of treatments for depression, anxiety, and other mental issues, and researchers may have stumbled across a ...
- Psychedelic toxins from toads could treat depression and anxietyon May 8, 2024 at 8:00 am
By Corryn WetzelA psychedelic compound secreted by a poisonous toad could help treat depression and anxiety, according to a study in mice.When frightened, Colorado river toads (Incilius alvarius) ...
via Bing News